Comment & Analysis
Biotech and the era of great liquidity
Risk appetite swells Initial public offerings (IPOs) and secondary offerings are the lifeblood of the biotech industry. Listing stocks gives early-stage companies access to the vast amount of cash necessary to advance drugs through clinical development and provides investors an opportunity to earn a return by investing in new biotech…
Continue Reading
Subscribe to unlock the full article and access premium financial content.
Click here to read the full story: Schroders